Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves' disease (GD), DCs have more active immune responses than those in healthy subjects. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on maturation of DC in GD patients. This study aims to evaluate the effect of oral 1α-D3 on DC maturation in GD patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr Cipto Mangunkusumo General Hospital
• Collaborator: Indonesia University
• Treatments: Alfacalcidol; Dihydroxycholecalciferols; Hydroxycholecalciferols

Criteria

Inclusion Criteria:

• Patients with Graves' disease and still have not gone into remission

• Willing to participate in the research

Exclusion Criteria:

• Pregnant patient

• Suffered from severe liver disease

• Suffered from severe kidney disease

• Taking vitamin D substitution therapy

• Suffered from another autoimmune disease

• Suffered from malignancy